- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03278886
St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (PETER PAIN)
August 7, 2020 updated by: Boston Medical Center
Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems
This study is a randomized controlled trial (RCT) to assess the feasibility, tolerability, and safety of using opioid receptor antagonists (naltrexone and nalmefene) to treat pain among HIV-infected persons with heavy alcohol use and chronic pain.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Pain is a common co-morbidity for HIV-infected patients.
Prevalence studies suggest that, on average, half of all HIV-infected persons suffer pain.
Chronic pain can lead to heavy alcohol use among HIV-infected persons, which may in turn be a barrier to treatment/control of HIV and contribute to spread of HIV.
Thus there is an urgent need to address pain among persons with HIV.
Opioid receptor antagonists such as naltrexone and nalmefene, which are licensed for treatment of alcohol use disorders, show promise as being effective and safe treatments for chronic pain among persons with HIV.
This study will pilot test novel pharmacotherapies (opioid receptor antagonists) to improve chronic pain among HIV-infected heavy drinkers.
The specific aims of the research is to assess the feasibility, tolerability and safety of using opioid receptor antagonists (low-dose naltrexone and nalmefene) to treat pain among HIV-infected persons with heavy alcohol use and chronic pain.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
St. Petersburg, Russian Federation, 197022
- First St. Petersburg Pavlov State Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years or older
- HIV-positive
- Chronic pain (present ≥3 mo) of moderate to severe intensity
- Heavy drinking past year (Based on NIAAA criteria: > 14 standard drinks per week/ > 4 drinks in a day for men; > 7 drinks in the past week/ > 3 drinks in a day for women)
- If female, negative pregnancy test and willing to use adequate birth control
- Provision of contact information for 2 contacts to assist with follow-up
- Stable address within 100 kilometers of St. Petersburg
- Possession of a telephone (home or cell)
- Able and willing to comply with all study protocols and procedures
Exclusion Criteria:
- Not fluent in Russian
- Cognitive impairment resulting in inability to provide informed consent based on research assessor (RA) assessment
- Known active TB or current febrile illness
- Breastfeeding
- Uncontrolled psychiatric illness (such as active psychosis) (i.e., answered yes to any of the following: past three month active hallucinations; mental health symptoms prompting a visit to the ED or hospital)
- History of hypersensitivity to naltrexone, nalmefene, or naloxone
- Current use (past week) of illicit or prescribed opiates as documented by either self-report or positive urine drug test
- Unwilling to abstain from opiates during the treatment period
- Current use of neuroleptics
- History of seizure disorder
- Known liver failure
- ALT/AST levels >5x normal
- History of Raynaud's Disease
- Planned surgeries in the next three months
- Enrolled in another HIV and/or substance use medication intervention study
- Taking naltrexone in the past 30 days
- Taking nalmefene in the past 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose naltrexone
Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
|
4.5 mg of low dose naltrexone taken once daily for 8 weeks
|
Experimental: Nalmefene
Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
|
18 mg of nalmefene taken once daily for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Tolerability Measured Via a 0-100 Visual Analog Scale
Time Frame: Primary endpoint at 8 weeks
|
Medication tolerability will be measured via a 0-100 visual analog scale.
Participants will be asked to indicate on a scale of 0-100, how well they have tolerated the study medication with 0 anchored as "cannot tolerate at all" and 100 as "tolerate perfectly well."
Higher numbers will be indicative of higher tolerability of the medication.
|
Primary endpoint at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Alcohol Use Defined as a Change in the Mean Number of Grams of Pure Ethanol Consumed Per Day From Baseline to 8 Weeks
Time Frame: Baseline, 8 weeks
|
Measured via 30 Day Alcohol Use Timeline Follow Back Method
|
Baseline, 8 weeks
|
Treatment Discontinuation Defined as Patient Self-report of Stopping Medication Anytime During the Treatment Period
Time Frame: 4 weeks, 8 weeks
|
Measured via one question asking participants if they had discontinued medication since their last visit.
Assessed at 4 and 8 week study visits.
|
4 weeks, 8 weeks
|
Adherence to Medication Defined as Self-report of Percentage of Study Medication Taken in the Past Two Weeks
Time Frame: Endpoint at 8 weeks
|
Measured by participants' drawing a line on a a Visual Analog Scale, which ranges from 0 to 100.
Higher numbers indicate higher adherence to study medication.
|
Endpoint at 8 weeks
|
Number of Participants With Adherence Assessed Via Riboflavin in the Urine Confirming Adherence
Time Frame: Endpoint at 8 weeks
|
Measured through visual inspection of the urine for the presence or absence of riboflavin using ultraviolet (UV) light at the long wave setting (33 mm) in a room with low ambient light.
|
Endpoint at 8 weeks
|
Reported Side Effects Using a Symptom Checklist, Plus an Open-ended Question
Time Frame: 2 weeks, 4 weeks, 6 weeks, 8 weeks
|
Measured via a 16-item symptom checklist with the option for participants to report any experienced side effects not on the checklist.
Side effect severity is rated by trained research assessors.
The checklist is asked at 2, 4, 6, and 8-week study visits.
|
2 weeks, 4 weeks, 6 weeks, 8 weeks
|
Medication Satisfaction Defined as a Score From 0-100 Measured Via the Treatment Satisfaction Questionnaire for Medication (TSQM), With Higher Scores Corresponding to Higher Treatment Satisfaction.
Time Frame: 4 weeks, 8 weeks
|
Measured via using the 14-item Treatment Satisfaction Questionnaire, which consists of 14 items that result in four domains: Effectiveness, Side Effects, Convenience and Global Satisfaction.
Higher scores indicate greater satisfaction with medication.
Assessed at 4 and 8 week study visits.
|
4 weeks, 8 weeks
|
Severe Hepatotoxicity Defined as AST/ALT >10X the Level of Normal
Time Frame: Endpoint at 8 weeks
|
Aminotransferase levels (AST/ALT) are tested to look for severe hepatotoxicity defined as AST/ALT > 10 times the level of normal.
|
Endpoint at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffrey H. Samet, MD, MA, MPH, Boston University/Boston Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 3, 2018
Primary Completion (Actual)
December 19, 2018
Study Completion (Actual)
December 19, 2018
Study Registration Dates
First Submitted
September 5, 2017
First Submitted That Met QC Criteria
September 8, 2017
First Posted (Actual)
September 12, 2017
Study Record Updates
Last Update Posted (Actual)
August 24, 2020
Last Update Submitted That Met QC Criteria
August 7, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-36491
- UH2AA026193 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
All data from the study will be placed into the URBAN ARCH repository.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Northwestern UniversityPfizer; Tibotec, IncCompletedHIV Infections | HIV-1 InfectionUnited States
Clinical Trials on Low dose naltrexone
-
Yale UniversityNational Institutes of Health (NIH)Completed
-
Jinnah Postgraduate Medical CentreCompleted
-
University of Alabama at BirminghamWithdrawn
-
Hadassah Medical OrganizationJerusalem Institute for Child DevelopmentUnknownPervasive Developmental DisorderIsrael
-
Washington University School of MedicineCompletedFrontal Fibrosing Alopecia | Lichen PlanopilarisUnited States
-
VA Office of Research and DevelopmentCompleted
-
Stanford UniversityWithdrawn
-
AgelessRxSuspended
-
Emory UniversitySuspendedHuman Immunodeficiency Virus | Chronic Neuropathic PainUnited States
-
University of Alabama at BirminghamStanford UniversityCompleted